The estimated Net Worth of Simon N.R. Harford is at least $2.27 Millón dollars as of 23 January 2023. Mr Harford owns over 102 units of Albireo Pharma Inc stock worth over $1,443,219 and over the last 16 years he sold ALBO stock worth over $134,618. In addition, he makes $687,784 as CFO & Treasurer at Albireo Pharma Inc.
Mr has made over 18 trades of the Albireo Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 102 units of ALBO stock worth $4,468 on 23 January 2023.
The largest trade he's ever made was selling 1,776 units of Albireo Pharma Inc stock on 19 January 2023 worth over $77,789. On average, Mr trades about 111 units every 33 days since 2008. As of 23 January 2023 he still owns at least 32,689 units of Albireo Pharma Inc stock.
You can see the complete history of Mr Harford stock trades at the bottom of the page.
Simon Nicolas Reade Harford is the CFO & Treasurer at Albireo Pharma Inc.
As the CFO & Treasurer of Albireo Pharma Inc, the total compensation of Mr Harford at Albireo Pharma Inc is $687,784. There are 7 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
Mr Harford is 60, he's been the CFO & Treasurer of Albireo Pharma Inc since . There are 6 older and 12 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
Simon's mailing address filed with the SEC is 47 HULFISH STREET, , PRINCETON, NJ, 08542.
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs y Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Inc executives and other stock owners filed with the SEC include: